PCI, CABG for Left Main CAD Have Similar 5-Year Outcomes
Findings reported for composite outcomes for 1,905 patients with left main coronary artery disease
Cardiovascular Disease
Severe Adverse Cardiovascular Events Associated With Ibrutinib
Risk up for severe, sometimes fatal, events, including supraventricular arrhythmias, CNS events
Heart Disease May Up Risk for Allopurinol-Linked Cutaneous AEs
Risk for hospital admission increased for allopurinol-associated severe cutaneous adverse reactions
Exposure to Pesticides Tied to Cardiovascular Disease Incidence
Correlation still significant after adjustment for other cardiovascular disease risk factors
Cardiorenal Disease Is the Most Common CVD Manifestation in Patients With T2D
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Linagliptin Noninferior for CV Risk in Early Type 2 Diabetes
Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk
Cardiovascular Risks Similar for Monthly, Short-Acting ESAs
Over a median 5.1 years, similar proportions of patients who received monthly methoxy polyethylene glycol epoetin beta arm and a reference group treated with conventional ESAs experienced major cardiovascular events and death.
Combo Antithrombotic Therapy Increases Bleeding Risk
Greatest risk seen in first year of treatment, but benefits of combo therapy continue after one year
Metformin Superior for Lowering CV Risk in Diabetics Who Progress to CKD
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial
The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran, an investigational twice-yearly cholesterol-lowering therapy. Inclisiran is a chemically synthesized small interfering RNA (siRNA) that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA. The subcutaneous (SC) injectable is being investigated for its ability…
Next post in Cardiovascular Disease (CVD)
